{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:19:16Z","timestamp":1791173956219,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T00:00:00Z","timestamp":1396396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP110609"],"award-info":[{"award-number":["RP110609"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>B cell receptor (<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>) signalling plays a critical role in the progression of several <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell malignancies, but its role in hairy cell leukaemia (<jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content>) is ambiguous. Bruton tyrosine kinase (<jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content>), a key player in <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content> signalling, as well as\nB cell migration and adhesion, can be targeted with ibrutinib, a selective, irreversible <jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content> inhibitor. We analysed <jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content> expression and function in <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> and analysed the effects of ibrutinib on <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> cells. We demonstrated uniform <jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content> protein expression in <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> cells. Ibrutinib significantly inhibited <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> proliferation and cell cycle progression. Accordingly, ibrutinib also reduced <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> cell survival after <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content> triggering with anti\u2010immunoglobulins and abrogated the activation of kinases downstream of the <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>3<jats:styled-content style=\"fixed-case\">K<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MAPK<\/jats:styled-content>). Ibrutinib also inhibited <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010dependent secretion of the chemokines <jats:styled-content style=\"fixed-case\">CCL<\/jats:styled-content>3 and <jats:styled-content style=\"fixed-case\">CCL<\/jats:styled-content>4 by <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content> cells. Interestingly, ibrutinib inhibited also <jats:styled-content style=\"fixed-case\">CXCL<\/jats:styled-content>12\u2010induced signalling, a key pathway for bone marrow homing. Collectively, our data support the clinical development of ibrutinib in patients with <jats:styled-content style=\"fixed-case\">HCL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12867","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T11:57:00Z","timestamp":1396439820000},"page":"177-188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["The bruton tyrosine kinase inhibitor ibrutinib (<scp>PCI<\/scp>\u201032765) blocks hairy cell leukaemia survival, proliferation and <scp>B<\/scp> cell receptor signalling: a new therapeutic approach"],"prefix":"10.1111","volume":"166","author":[{"given":"Mariela","family":"Sivina","sequence":"first","affiliation":[{"name":"Department of Leukemia M. D. Anderson Cancer Center The University of Texas Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology National Cancer Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Arons","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology National Cancer Institutes of Health Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia M. D. Anderson Cancer Center The University of Texas Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia M. D. Anderson Cancer Center The University of Texas Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-201731"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.777837"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3182"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452607"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170415"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.568649"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2012.152"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_2_8_12_1","first-page":"246","article-title":"Exquisite sensitivity of refractory hairy\u2010cell leukemia to BRAF inhibition with Vemurafenib","volume":"35","author":"Dietrich S.","year":"2012","journal-title":"Onkologie"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402107"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07668.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.975"},{"key":"e_1_2_8_16_1","first-page":"266","article-title":"Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B\u2010cell malignancies","volume":"90","author":"Forconi F.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.12282","article-title":"Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia","volume":"93","author":"Forconi F.","journal-title":"Hematologica"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.530362"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"31a","DOI":"10.1182\/blood.V116.21.55.55","article-title":"CAL\u2010101, an isoform\u2010selective inhibitor of phosphatidylinositol 3\u2010kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"116","author":"Furman R.R.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19399"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.11.012"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2006.06.012"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040544"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212837"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351502"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.05.003"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307249"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011866"},{"key":"e_1_2_8_38_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.","year":"2008"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3485"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.163"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0818"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723449"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379339"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12867","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:59:35Z","timestamp":1696352375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/bjh.12867"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12867","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,2]]},"assertion":[{"value":"2013-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}